ArticlePloS one2022

Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.

Yung-Hsin Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.